Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.

Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F.

Am J Clin Oncol. 2001 Apr;24(2):143-7.

PMID:
11319288
2.

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).

Pinto C, Marino A, De Pangher Manzini V, Benedetti G, Galetta D, Mazzanti P, Del Conte G, dell'Amore D, Piana E, Giaquinta S, Lopez M, Martoni A.

Lung Cancer. 2006 May;52(2):199-206. Epub 2006 Mar 20.

PMID:
16542747
3.
4.

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.

Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R.

Cancer. 1997 May 15;79(10):1897-902.

PMID:
9149015
5.

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.

Astoul P, Picat-Joossen D, Viallat JR, Boutin C.

Cancer. 1998 Nov 15;83(10):2099-104.

PMID:
9827714
6.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

7.

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M.

Lung Cancer. 2001 Feb-Mar;31(2-3):303-10.

PMID:
11165411
8.

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.

J Clin Oncol. 2006 Mar 20;24(9):1443-8.

PMID:
16549838
9.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
10.

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.

Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, Lecomte J, Collon T, Mommen P, Sculier JP; European Lung Cancer Working Party (ELCWP).

Lung Cancer. 2005 Oct;50(1):75-82.

PMID:
16005104
11.

Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM.

J Clin Oncol. 2005 May 20;23(15):3495-501.

PMID:
15908659
12.

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada.

J Clin Oncol. 2005 Oct 1;23(28):6881-9.

PMID:
16192580
13.

A phase II study of pirarubicin in malignant pleural mesothelioma.

Kaukel E, Koschel G, Gatzemeyer U, Salewski E.

Cancer. 1990 Aug 15;66(4):651-4.

14.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA; Pemetrexed Expanded Access Program Investigators.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.

PMID:
17092602
15.

A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.

Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L, Fontanini G, Mussi A.

Eur J Cardiothorac Surg. 2007 Mar;31(3):529-33; discussion 533-4. Epub 2006 Dec 26.

PMID:
17188885
16.

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Samuels BL, Herndon JE 2nd, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ.

Cancer. 1998 Apr 15;82(8):1578-84.

PMID:
9554537
17.

Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.

Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P.

Lung Cancer. 1994 Sep;11(3-4):299-303.

PMID:
7812707
18.

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.

Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM.

Lung Cancer. 2001 Jan;31(1):67-72.

PMID:
11162868
19.

Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.

Maisano R, Caristi N, Toscano G, Aragona M, Spadaro P, Amadio P, Mare M, Zavettieri M, La Torre F.

Tumori. 2001 Nov-Dec;87(6):391-3.

PMID:
11989592
20.

Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.

Gridelli C, Pepe R, Airoma G, Incoronato P, Rossi A, Palazzolo G, Bianco AR.

Tumori. 1992 Dec 31;78(6):380-2.

PMID:
1297232

Supplemental Content

Support Center